Guidance, NICE advice and quality standards in development | Guidance

Showing 61 to 70 of 404

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243]	Technology appraisal guidance	24 May 2019
Cabozantinib for treating advanced neuroendocrine tumours that have progressed after systemic treatment ID6474	Technology appraisal guidance	TBC
Cabozantinib with nivolumab and ipilimumab for untreated intermediate- or poor-risk advanced renal cell carcinoma [ID6330]	Technology appraisal guidance	TBC
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]	Technology appraisal guidance	TBC
Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment [ID6370]	Technology appraisal guidance	5 March 2025
Capivasertib with paclitaxel for untreated metastatic triple-negative breast cancer [ID6383]	Technology appraisal guidance	TBC
Cardiometabolic disease prevention and treatment guidelines	NICE guideline	TBC
Cardiovascular risk assessment and lipid modification	Quality standard	23 July 2025
Cediranib with olaparib for treating recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer after 3 therapies [ID1639]	Technology appraisal guidance	TBC
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer [ID3949]	Technology appraisal guidance	30 April 2025